FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2344726032> ?p ?o ?g. }

• W2344726032 abstract "Purpose A phase I dose escalation study was performed to determine the maximum tolerated dose (MTD) of intercalated dosing of BMS-690514, a reversible oral panHER/ VEGF receptor inhibitor, combined with paclitaxel/carboplatin (PC) in advanced solid tumors. Secondary endpoints included safety, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and preliminary efficacy. Experimental design Patients received fixed doses of P (200 mg/m 2 ) and C (AUC 6 mg/mL min) q21 days with intercalated BMS-690514 (Days 4‐19) starting at 100 mg/ day and increasing by 50 mg/day using a 3 ? 3 dose escalation design until the MTD was reached. Twenty additional patients were enrolled in the expansion cohort at the recommended phase II dose (RP2D). Results The MTD was reached at 150 mg/day. DLTs included grade 3 thrombosis at 100 mg (1 patient) and grade 3 diarrhea at 150 mg (1 patient) and 200 mg (2 patients). Serious adverse events (AEs) occurring in 20/37 patients included neutropenia (n = 5), diarrhea (n = 4), pulmonary embolism (n = 3), and simultaneous dehydration, acute renal failure, and febrile neutropenia (n = 2). BMS-690514-related AEs included diarrhea (97 %), acneiform rash (60 %), fatigue (43 %), nausea (30 %), and anorexia (30 %). There were no treatment-related deaths. Sequential intermittent administration of PC did not affect the PK of BMS-690514. Of the 32 patients evaluable for efficacy, there were 12 partial responses including five patients with non-small-cell lung cancer and 12 patients with stable disease. Conclusions The MTD of intercalated BMS-609514 combined with PC was 150 mg/day. This approach was tolerable with manageable toxicities and antitumor activity in a variety of solid tumor types." @default.
• W2344726032 created "2016-06-24" @default.
• W2344726032 creator A5025646273 @default.
• W2344726032 creator A5034035584 @default.
• W2344726032 creator A5041114807 @default.
• W2344726032 creator A5043124797 @default.
• W2344726032 creator A5044829936 @default.
• W2344726032 creator A5057726848 @default.
• W2344726032 creator A5070256948 @default.
• W2344726032 creator A5071502859 @default.
• W2344726032 creator A5071524213 @default.
• W2344726032 creator A5077884585 @default.
• W2344726032 creator A5077995735 @default.
• W2344726032 creator A5085908317 @default.
• W2344726032 date "2013-01-01" @default.
• W2344726032 modified "2023-09-27" @default.
• W2344726032 title "A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies Laura Q. M. ChowDerek I. JonkerGrace K. DyGarth Nicholas • Catherine FortinDaniel PatriciaAlex A. AdjeiChandra P. Belani • Ashok GuptaJong-Soon ParkSteven ZhangEric I. SbarScott A. Laurie" @default.
• W2344726032 cites W1981117703 @default.
• W2344726032 cites W1986989909 @default.
• W2344726032 cites W1989645145 @default.
• W2344726032 cites W1991568191 @default.
• W2344726032 cites W1998280666 @default.
• W2344726032 cites W2000292756 @default.
• W2344726032 cites W2005216767 @default.
• W2344726032 cites W2032371685 @default.
• W2344726032 cites W2039138983 @default.
• W2344726032 cites W2041814933 @default.
• W2344726032 cites W2053394601 @default.
• W2344726032 cites W2067780032 @default.
• W2344726032 cites W2071274102 @default.
• W2344726032 cites W2075960059 @default.
• W2344726032 cites W2086913687 @default.
• W2344726032 cites W2093089862 @default.
• W2344726032 cites W2095583145 @default.
• W2344726032 cites W2098070636 @default.
• W2344726032 cites W2109240520 @default.
• W2344726032 cites W2110835998 @default.
• W2344726032 cites W2115330744 @default.
• W2344726032 cites W2122023073 @default.
• W2344726032 cites W2127101185 @default.
• W2344726032 cites W2132128432 @default.
• W2344726032 cites W2133407439 @default.
• W2344726032 cites W2133474937 @default.
• W2344726032 cites W2135400147 @default.
• W2344726032 cites W2145835533 @default.
• W2344726032 cites W2148218538 @default.
• W2344726032 cites W2152755651 @default.
• W2344726032 cites W2157099922 @default.
• W2344726032 cites W2157769714 @default.
• W2344726032 cites W2159370421 @default.
• W2344726032 cites W2161557170 @default.
• W2344726032 cites W2162724777 @default.
• W2344726032 cites W2168783885 @default.
• W2344726032 cites W2222964070 @default.
• W2344726032 cites W2228157008 @default.
• W2344726032 cites W2397584489 @default.
• W2344726032 cites W2534450951 @default.
• W2344726032 cites W2756135254 @default.
• W2344726032 cites W51288761 @default.
• W2344726032 cites W74687677 @default.
• W2344726032 hasPublicationYear "2013" @default.
• W2344726032 type Work @default.
• W2344726032 sameAs 2344726032 @default.
• W2344726032 citedByCount "0" @default.
• W2344726032 crossrefType "journal-article" @default.
• W2344726032 hasAuthorship W2344726032A5025646273 @default.
• W2344726032 hasAuthorship W2344726032A5034035584 @default.
• W2344726032 hasAuthorship W2344726032A5041114807 @default.
• W2344726032 hasAuthorship W2344726032A5043124797 @default.
• W2344726032 hasAuthorship W2344726032A5044829936 @default.
• W2344726032 hasAuthorship W2344726032A5057726848 @default.
• W2344726032 hasAuthorship W2344726032A5070256948 @default.
• W2344726032 hasAuthorship W2344726032A5071502859 @default.
• W2344726032 hasAuthorship W2344726032A5071524213 @default.
• W2344726032 hasAuthorship W2344726032A5077884585 @default.
• W2344726032 hasAuthorship W2344726032A5077995735 @default.
• W2344726032 hasAuthorship W2344726032A5085908317 @default.
• W2344726032 hasConcept C111113717 @default.
• W2344726032 hasConcept C112705442 @default.
• W2344726032 hasConcept C126322002 @default.
• W2344726032 hasConcept C197934379 @default.
• W2344726032 hasConcept C2776256026 @default.
• W2344726032 hasConcept C2776694085 @default.
• W2344726032 hasConcept C2777063308 @default.
• W2344726032 hasConcept C2778239845 @default.
• W2344726032 hasConcept C2778496288 @default.
• W2344726032 hasConcept C2778570526 @default.
• W2344726032 hasConcept C2778850193 @default.
• W2344726032 hasConcept C2780580376 @default.
• W2344726032 hasConcept C2781451048 @default.
• W2344726032 hasConcept C71924100 @default.
• W2344726032 hasConcept C90924648 @default.
• W2344726032 hasConcept C98274493 @default.
• W2344726032 hasConceptScore W2344726032C111113717 @default.
• W2344726032 hasConceptScore W2344726032C112705442 @default.
• W2344726032 hasConceptScore W2344726032C126322002 @default.
• W2344726032 hasConceptScore W2344726032C197934379 @default.
• W2344726032 hasConceptScore W2344726032C2776256026 @default.
• W2344726032 hasConceptScore W2344726032C2776694085 @default.
• W2344726032 hasConceptScore W2344726032C2777063308 @default.

• next